CAPRCapricor Therapeutics, Inc.

HealthcareUSD
$30.40

The financials

Capricor Therapeutics, Inc. by the numbers

For the full year FY2025, revenue was $0 (−100% year on year) and net income −$105M.

Capricor Therapeutics, Inc. income statement, Q1 2026 against the same quarter a year earlier
Income statementQ1 2026Q1 2025Change
Operating income−$37M−$25Mn/a
Net income−$34M−$24Mn/a
Diluted EPS−$0.59−$0.53n/a

Biotechnology

Ranks #113 of 145 by Smart Score

Compare peers
SNDX-0.85%
Syndax Pharmaceuticals, Inc.
ZYME-2.2%
Zymeworks Inc.
RXRX+3.4%
Recursion Pharmaceuticals, Inc.
GHRS+3.0%
GH Research PLC
TSHA-11%
Taysha Gene Therapies, Inc.
ANAB+2.1%
AnaptysBio, Inc.